2.98 USD
↗ 0.10 (3.47%)AT CLOSE (11:59 AM EDT)
Editas Medicine, Inc. Common Stock
EDITNASDAQ • USD
2.97
↘ 0.01 (0.34%)
POST MARKET (AS OF 06:21 PM EDT)
Post Market
AS OF 06:21 PM EDT
2.97
↘ 0.01 (0.34%)
Market: CLOSED
Editas Medicine, Inc. Common Stock (EDIT) trades at $2.98 per share. The technical outlook is "Neutral" and the fundamental picture shows "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, negative Return on Equity and a bullish Golden Cross on the moving averages. On the valuation front, EDIT trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Jul 17, 2026.
Open?$2.80
High?$3.03
Low?$2.77
Prev. Close?$2.88
Volume?1.7M
Avg. Volume?2.7M
VWAP?$2.94
Rel. Volume?0.65x
Bid / Ask
Bid?$2.57 × 100
Ask?$3.42 × 100
Spread?$0.85
Midpoint?$3.00
Valuation & Ratios
Market Cap?442.0M
Shares Out?97.9M
Float?148.7M
Float %?96.9%
P/E Ratio?N/A
P/B Ratio?100.27
EPS?-$0.71
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Employees
87
Market Cap
442.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-02-03
Address
11 HURLEY ST.
CAMBRIDGE, MA 02141
Phone: 617-401-9000
CAMBRIDGE, MA 02141
Phone: 617-401-9000
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?92
Short Sent.?35
Piotroski F-Score?3/9Weak
Altman Z-Score?-15.11Distress
Confidence?51%Low
Short InterestHigh
Short % of Float?15.11%High
Short Interest?22.5M
Days to Cover?7.2
Free Float148.7M
Avg Daily Volume3.1M
Settlement Date2026-06-30
Financial Health
Current Ratio?3.22Strong
Quick Ratio?3.22Strong
Cash Ratio?3.11Strong
Debt/Equity?12.40High
ValuationRICHLY VALUEDvs 3 peers + S&P 500
Score50/100
P/E?N/A▾
P/B?100.27HIGH▾
Peers25
S&P3
P/S?11.42HIGH▾
Peers100
S&P6
P/FCF?N/A▾
EV/EBITDA?-4.4CHEAP▾
S&P97
EV/Sales?9.64HIGH▾
Peers100
S&P12
Returns & Efficiency
ROE?-2,471.7%WEAK▾
S&P3
ROA?-73.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-141088000
Enterprise Value?$373.0M
Fundamentals ratios updated end of day